Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, EVOFEM BIOSCIENCES, INC. reported revenue of $20M, up 4.2% year over year. Operating margin was 16.7% and net margin 1.9%, on a free-cash-flow margin of -9.9% with capital expenditure at 0.0% of revenue. Every figure is computed directly from EVFM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $20M | 16.7% | 1.9% |
| FY2024 | $19M | -39.6% | -45.8% |
| FY2023 | $18M | -98.0% | 290.8% |
| FY2022 | $17M | -499.6% | -455.5% |
| FY2021 | $8M | -2023.3% | -2489.0% |
How does EVFM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.